Asia-Pacific journal of clinical oncology最新文献

{"title":"The Importance of Driver-Targeted Therapy Among Patients With Lung Cancer Initially Diagnosed in the Intensive Care Unit","authors":"Yi-Chun Hsiao,&nbsp;Wei-Fan Ou,&nbsp;Po-Hsin Lee,&nbsp;Yu-Wei Hsu,&nbsp;Yen-Hsiang Huang,&nbsp;Kuo-Hsuan Hsu,&nbsp;Jeng-Sen Tseng,&nbsp;Gee-Chen Chang,&nbsp;Tsung-Ying Yang","doi":"10.1111/ajco.70149","DOIUrl":"10.1111/ajco.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients who had been diagnosed with lung cancer during intensive care unit (ICU) admission showed poor prognosis. This research investigated the clinical characteristics related to the outcomes of these patients and focused on the potential benefit of driver-targeted therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From February 2011 to October 2022, we included patients who were initially diagnosed with lung cancer during ICU admission in Taichung Veterans General Hospital. We evaluated their clinicopathological factors, overall survival, and hospital discharge outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included a total of 57 patients. The most frequent reasons for ICU entry were central nervous system metastasis (36.8%), respiratory tract infections (26.3%), and tumor with main airway compression (15.8%). The median APACHE II score was 23 (range: 6–40). Bronchoscopy (47.4%) followed by brain craniotomy (22.8%) were the most common biopsy methods, while adenocarcinoma (68.4%) accounted for the most common histology. Eighteen patients received driver-targeted therapy. Tumor as the primary reason for ICU admission (aOR 4.90 [95% CI 1.22–19.6], <i>p = </i>0.025) and driver-targeted therapy (aOR 2.80 [95% CI 1.01–7.69], <i>p = </i>0.048) both independently predicted a higher chance of ventilator-independent hospital discharge. Significant factors for a longer overall survival included tumor as the primary reason for ICU admission (aHR 0.63 [95% CI 0.40–0.99], <i>p = </i>0.046), a lower baseline APACHE II score (aHR 0.62 [95% CI 0.40–0.96], <i>p = </i>0.031), and driver-targeted therapy (aHR 0.17 [95% CI 0.05–0.51], <i>p = </i>0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Driver-targeted therapy was associated with a favorable hospital discharge outcome and a longer overall survival. Performing a biopsy to confirm diagnosis and oncogenic driver(s) testing are recommended.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"844-852"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Toxicity With Trastuzumab Emtansine and Concurrent Radiotherapy: Non-Consecutive Case Series","authors":"Philip Carroll,&nbsp;Jade Soo,&nbsp;Keelan Byrne,&nbsp;Michelle White,&nbsp;Yoland Antill,&nbsp;Karen Taylor,&nbsp;Jennifer Tan,&nbsp;Phillip Tran,&nbsp;Steven David","doi":"10.1111/ajco.70146","DOIUrl":"10.1111/ajco.70146","url":null,"abstract":"<div>\u0000 \u0000 <p>In the setting of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, trastuzumab emtansine (T-DM1) is associated with improvements in both relapse-free and overall survival for patients with residual invasive disease after receiving neoadjuvant chemotherapy and HER2-targeted therapy. Many of these patients also undergo adjuvant radiotherapy treatment (RT); however, outside of the KATHERINE trial, there is little published data regarding the safety of this as a concurrent therapy, or when used in close sequential proximity. We report on ten cases at our institution whereby enhanced radiotherapy toxicity was observed when RT was delivered concurrently, or in close proximity to, T-DM1. Five patients experienced significant pulmonary toxicity, including early-onset radiation pneumonitis (RP), recurrent RP despite appropriate treatment, and out-of-field RP. Two patients experienced unexpected enhanced skin toxicity, one with prolonged radiation dermatitis followed by telangiectasia formation and the other with breast cellulitis requiring hospital admission. A further two developed rib fractures, one requiring surgical management and hyperbaric treatment. A final patient developed myositis. This case series supports the hypothesis that T-DM1 may enhance radiation toxicity, potentially due to its microtubule inhibitor emtansine components. Further studies are recommended to assess the potential toxicities and sequencing when combining treatment modalities. We advise clinicians to remain vigilant for unexpected toxicities and consider the potential risks in patient management of adjuvant radiotherapy when combined with T-DM1.</p>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"881-890"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncology Inpatient Resuscitation Planning and Long-Term “Rapid Response Call” Outcomes","authors":"Dhanashree Tikhe,&nbsp;Petition Nhira,&nbsp;Megan Kepreotis,&nbsp;Fiona Day","doi":"10.1111/ajco.70129","DOIUrl":"10.1111/ajco.70129","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Resuscitation plans document the mutually agreed medical care of hospital inpatients in an acute deterioration, including decisions regarding cardiopulmonary resuscitation (CPR), rapid response calls (RRCs), and other specific interventions. The aim of this study was to examine the resuscitation plan completion rate among all medical oncology inpatients after the introduction of a 100% completion target. We concurrently examined the outcomes of medical oncology inpatients subject to a RRC to investigate medium- and long-term patient outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective real-time longitudinal audit of resuscitation plan completion was conducted of all medical oncology admissions over 3 months. Completion of a resuscitation form at any time, and within 72 h, was recorded. RRC information was obtained from the preceding 6 months. RRC data included event time and trigger, patient tumor type and treatment intent, available resuscitation plan at RRC, patient disposition after RRC, survival to discharge, and to future cancer treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 326 hospitalizations, 60% included a completed resuscitation form and 56% within 72 h. There were 53 RRCs in 39 individual patients. Most RRCs were after hours (64%) and without an available resuscitation plan (92%). Additionally, 91% of RRCs were in patients receiving palliative cancer treatment; 53% did not survive to discharge, and 76% received no further systemic cancer treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Resuscitation plan completion remains significantly below the aspirational 100% and requires targeted implementation strategies. A proportion of oncology patients receiving palliative cancer treatment continue to be managed in hospital without a resuscitation plan and undergo RRCs despite a poor prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"801-807"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of Focal 18F-FDG Uptake on Positron Emission Tomography/Computed Tomography to Ultrasonography-Based Malignancy Risk Assessment in Incidentally Detected Thyroid Nodules","authors":"Yusuf Öztürk,&nbsp;Buğra Kaya,&nbsp;Yusuf Karadeniz,&nbsp;Melia Karaköse","doi":"10.1111/ajco.70154","DOIUrl":"10.1111/ajco.70154","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study sought to evaluate the incremental contribution of the presence of focal FDG uptake and SUVmax on PET/CT in predicting malignancy in incidentally detected thyroid nodules when assessed in conjunction with ultrasonography-based risk features.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective study, 304 incidentally detected thyroid nodules identified on PET/CT and confirmed by cytology and/or histopathology were analyzed. The clinical, ultrasonographic, and PET/CT findings were meticulously documented. The presence or absence of focal FDG uptake was subsequently visually assessed on PET/CT images, and SUVmax values were also calculated for FDG-avid nodules. The factors associated with malignancy were evaluated using univariate and multivariate logistic regression analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall malignancy rate was 12.2%. The analysis revealed that focal FDG uptake was observed in 97.3% of malignant nodules and in 65.9% of benign nodules (<i>p</i> &lt; 0.001). Among FDG-avid nodules, SUVmax values were significantly higher in malignant lesions (<i>p</i> &lt; 0.001). However, in multivariate models incorporating ultrasonography-based risk features, focal FDG uptake demonstrated only borderline statistical significance (<i>p</i> = 0.055), while SUVmax was not independently associated with malignancy (<i>p</i> = 0.360).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The absence of focal FDG uptake on PET/CT was associated with a very low likelihood of malignancy in incidentally detected thyroid nodules. However, focal FDG uptake should be interpreted in conjunction with ultrasonography-based risk features rather than as an independent decision-making criterion. Although SUVmax values were higher in malignant FDG-avid nodules, SUVmax did not provide independent or additional diagnostic value beyond ultrasonography-based risk assessment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"861-869"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Dexamethasone Versus N-Acetylcysteine in Prevention of Post-Embolization Syndrome in Hepatocellular Carcinoma Patients: A Multicenter Randomized, Double-Blind, Double-Dummy, Non-Inferiority Trial","authors":"Padungkeat Karasin,&nbsp;Kittithat Tantitanawat,&nbsp;Chanchai Charonpongsuntorn,&nbsp;Anuchit Suksamai,&nbsp;Sakkarin Chirapongsathorn","doi":"10.1111/ajco.70127","DOIUrl":"10.1111/ajco.70127","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Post-embolization syndrome (PES) is a frequent complication after hepatocellular carcinoma (HCC) treatment. This study compared dexamethasone (DEX) versus N-acetylcysteine (NAC) for efficacy and safety in preventing PES at 48 h after transcatheter arterial chemoembolization (TACE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This Phase 3, randomized (1:1), double-blind, double-dummy, parallel-group, non-inferiority study, included patients with early- to intermediate-stage HCC (BCLC Stages A–B) without macrovascular invasion who were candidates for TACE. Participants were randomly assigned to receive either an intravenous single dose of 8 mg DEX or NAC as part of the periprocedural TACE protocol.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 85 patients were included in the outcome analysis. PES incidence was non-inferior between groups (difference proportion DEX-NAC 0.02, [95% CI: −0.13 to 0.17]). However, subgroup symptoms’ analysis showed significantly greater reduction in abdominal pain (87.5% vs. 55.3%, <i>p</i> = 0.002) and fever (52.5% vs. 28.9%, <i>p</i> = 0.035) in DEX group compared to NAC group. Liver decompensation was significantly greater reduction in the DEX group than the NAC group (90% vs. 52.6%, <i>p</i> &lt; 0.001). Anaphylactoid reactions (18.4%) were observed exclusively in the NAC group. Multivariate analysis showed preexisting high serum ALT was associated with an increased risk of developing PES (OR: 1.05; 95% CI: 1.01–1.08), and a higher chemotherapy dosage emerged as an independent risk factor for post-TACE liver decompensation (OR: 1.00; 95% CI: 0.84–0.99).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PES incidence was non-inferior between groups. However, at 48 h post-TACE, the DEX regimen was associated with a significant reduction in fever, pain, and liver decompensation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: TCTR20250607002.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"780-790"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-Specific Membrane Antigen Positron Emission Tomography in Japan: An Implementation Gap in the Era of Global Adoption","authors":"Hiroshi Yaegashi,&nbsp;Nat Lenzo,&nbsp;Kouji Izumi,&nbsp;Atsushi Mizokami","doi":"10.1111/ajco.70125","DOIUrl":"10.1111/ajco.70125","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"893-894"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non-Randomized Comparative Interventional Study","authors":"Mehdi Karimi,&nbsp;Samira Pirzad,&nbsp;Kimia Habibi,&nbsp;Masoud Mirkazemi","doi":"10.1111/ajco.70153","DOIUrl":"10.1111/ajco.70153","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Giant cell tumor of bone (GCTB) is a rare, locally aggressive osteolytic neoplasm associated with a substantial risk of local recurrence and challenging surgical management. Denosumab, a monoclonal antibody, has emerged as a promising therapeutic option. This study evaluates the efficacy of denosumab as a neoadjuvant therapy in patients with Grade III GCTB, with particular emphasis on tumor recurrence, ossification, and surgical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective, non-randomized comparative interventional study, 34 adults with histologically confirmed Campanacci Grade III GCTB were enrolled and prospectively followed. Sixteen patients received neoadjuvant denosumab and 18 contemporaneous patients underwent surgery without neoadjuvant denosumab. Treatment allocation was based on routine clinical decision-making and patient-specific factors rather than randomization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the 18-month follow-up period, local recurrence occurred in 2 of 16 patients (12.5%) in the denosumab intervention group and in 8 of 18 patients (44.4%) in the comparison group (<i>p = </i>0.063). Radiological ossification was observed in all patients in the denosumab group and in none of the patients in the comparison group. Curettage and cementation were performed in 14 patients (87.5%) in the intervention group and 12 patients (66.7%) in the comparison group; this difference was not statistically significant (<i>p = </i>0.233). Qualitative histopathological assessment of available specimens from denosumab-treated patients demonstrated marked depletion or disappearance of osteoclast-like giant cells, accompanied by treatment-related changes including new bone formation, fibrosis, and hemorrhage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this study, neoadjuvant denosumab was associated with complete radiological ossification, qualitative histopathological changes characterized by marked depletion of osteoclast-like giant cells, and numerically lower observed local recurrence and greater use of curettage and cementation, although the latter two between-group differences were not statistically significant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"853-860"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating COSA Psychosocial Guidelines into Practice: Learnings from a National Workshop on Post-Acute Care for Adolescents and Young Adults with Cancer","authors":"Darren Haywood,&nbsp;Sandra Gleaves,&nbsp;Joanna Fardell,&nbsp;Rachel Houweling,&nbsp;Hayley Griffin,&nbsp;Jennifer Haywood,&nbsp;Nicolas H. Hart,&nbsp;Ursula M. Sansom-Daly","doi":"10.1111/ajco.70155","DOIUrl":"10.1111/ajco.70155","url":null,"abstract":"&lt;p&gt;Adolescent and young adult (AYA) cancer survivors (i.e., people aged 15 to 25 years diagnosed and living with and beyond cancer) experience significant psychosocial challenges that intersect with their usual developmental needs and trajectories as young people in society [&lt;span&gt;1&lt;/span&gt;]. Consequently, this results in a third of AYA cancer survivors reporting clinically significant psychosocial distress [&lt;span&gt;2&lt;/span&gt;]. Further, AYA cancer survivors experience challenges in navigating education, employment and relationships, as well as identity formation, developing independence, and maintaining family bonds [&lt;span&gt;1, 3&lt;/span&gt;]. Together, these challenges underscore the requirement of age-appropriate psychosocial care for AYA cancer survivors across each stage of the cancer continuum [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;One stage of the cancer continuum that poses unique psychosocial challenges, and which is often neglected, is the post-acute period (0 to 5 years post-treatment completion) [&lt;span&gt;5&lt;/span&gt;], which precedes long-term survivorship (≥5 years post-treatment completion). The post-acute period marks a major shift for AYAs, their families, and healthcare teams, from intensive medical treatment to a stronger focus on quality of life, physical recovery and development, and psychosocial well-being, both now and in the long term [&lt;span&gt;6&lt;/span&gt;]. During this stage, the priority is to prepare the young person for post-treatment life by ensuring that necessary supports are in place, including best-practice psychosocial support to effectively address common survivorship challenges that arise during this period. Approximately 90% of AYA cancer survivors in the post-acute period report experiencing significant emotional concerns [&lt;span&gt;7&lt;/span&gt;], with 80% reporting unmet psychosocial needs [&lt;span&gt;1, 8&lt;/span&gt;]. Psychosocial challenges commonly reported include anxiety, depression, and fear of recurrence, in addition to developmental challenges, including autonomy and fertility preservation [&lt;span&gt;1, 8&lt;/span&gt;]. Commonly reported psychosocial unmet needs include support related to education, employment, financial stress, and navigating relationships [&lt;span&gt;1, 7-9&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Healthcare professionals of all disciplines working with AYA cancer survivors require guidance on best-practice psychosocial wellbeing screening, assessment, and care planning tailored to the post-acute period. However, this has been largely neglected. In Australia, this gap is particularly relevant given the availability of nationally coordinated, developmentally informed AYA cancer care services, including through the Australian Youth Cancer Service (YCS), which was established to deliver age‑appropriate, multidisciplinary care across jurisdictions [&lt;span&gt;10&lt;/span&gt;]. These services explicitly identify psychosocial care as a core component of quality AYA cancer services; however, understanding and applying best-practice management of AYA cancer survivors has been challenging due to t","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"775-779"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Need of Rescue: Modernizing and Redefining Treatment Intent in Oncology","authors":"Howard Yu,&nbsp;Roland Yeghiaian-Alvandi","doi":"10.1111/ajco.70115","DOIUrl":"10.1111/ajco.70115","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"891-892"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147621603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a Modified Proprietary Electronic Patient Reported Outcome Measures Tool for Monitoring Toxicities Associated With Systemic Chemotherapy","authors":"Tali Lang,&nbsp;T. B. N. Hoang,&nbsp;Josh Farrington,&nbsp;Kirsten Seletto,&nbsp;Gary Richardson","doi":"10.1111/ajco.70128","DOIUrl":"10.1111/ajco.70128","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To assess the feasibility of a specialized ePROMs tool measuring toxicity encountered by oncology patients during routine outpatient intravenous chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A proprietary ePROMs tool underwent modification to incorporate a questionnaire focused on nine chemotherapy-associated toxicities within Cabrini Hospital. This tool was piloted in a group of oncology patients receiving intravenous chemotherapy at two outpatient chemotherapy units in a private Australian healthcare center. Patients registered the toxicities and severity through the modified ePROMs tool weekly from the onset of treatment. The collected data were correlated with the specific chemotherapy drugs administered.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 133 enrolled patients, 102 completed the 12-week study. The median age was 61 years (range: 23–81), 94 participants were female (71%), and the most common cancer subtypes were breast (26%), gastrointestinal (25%), and gynecological (19%) cancers. Post-study feedback was gathered from 76 of the 102 participants (75% [95% confidence interval {CI}: 69.2–86.0]) who completed the 12-week program. These participants rated the ePROMs tool as user-friendly (100% [95% CI: 96.4–100.0]) and understandable (99% [95% CI: 96.4–100.0]), with a majority endorsing its usage to other patients receiving chemotherapy (96% [95% CI: 94.7–99.9]) and a preference to continue its usage (87% [95% CI: 79.2–93.0]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The findings of the study indicate that implementation of an ePROMs tool for real-time reporting of chemotherapy toxicities during routine outpatient care is feasible and promising. Positive patient feedback highlights its prospective role in patient-centered care and improving the understanding and documentation of chemotherapy toxicities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 6","pages":"791-800"},"PeriodicalIF":2.1,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}